BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34972752)

  • 1. The Association of the Lymphocyte-to-C-Reactive-Protein Ratio With Gastric Cancer Patients Who Receive Curative Treatment.
    Aoyama T; Nakazano M; Nagasawa S; Hara K; Komori K; Tamagawa H; Maezawa Y; Segami K; Kano K; Ogata T; Yukawa N; Rino Y; Oshima T
    In Vivo; 2022; 36(1):482-489. PubMed ID: 34972752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impacts of lymphocyte-to-C-reactive protein ratio for esophageal cancer patients who receive curative treatment.
    Aoyama T; Nagasawa S; Nakazono M; Segami K; Tamagawa H; Tamagawa A; Hara K; Oshima T; Yukawa N; Masuda M; Rino Y
    J Cancer Res Ther; 2023; 19(3):556-561. PubMed ID: 37470574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric Cancer.
    Aoyama T; Nakazono M; Segami K; Nagasawa S; Kano K; Yamada T; Maezawa Y; Hara K; Hashimoto I; Suematsu H; Watanabe H; Takahashi K; Numata M; Tamagawa H; Yukawa N; Rino Y; Ogata T; Oshima T
    In Vivo; 2021; 35(6):3475-3482. PubMed ID: 34697184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer?
    Angin YS; Yildirim M; Dasiran F; Okan I
    ANZ J Surg; 2021 Jul; 91(7-8):1521-1527. PubMed ID: 33956378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of the Prealbumin Level in Gastric Cancer Patients Who Receive Curative Treatment.
    Aoyama T; Nakazono M; Segami K; Nagasawa S; Kano K; Hara K; Maezawa Y; Hashimoto I; Suematsu H; Watanabe H; Komori K; Tamagawa H; Yukawa N; Rino Y; Ogata T; Oshima T
    J Gastrointest Cancer; 2023 Mar; 54(1):27-34. PubMed ID: 34921671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined analysis of preoperative and postoperative lymphocyte-C-reactive protein ratio precisely predicts outcomes of patients with gastric cancer.
    Miyatani K; Sawata S; Makinoya M; Miyauchi W; Shimizu S; Shishido Y; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Fujiwara Y
    BMC Cancer; 2022 Jun; 22(1):641. PubMed ID: 35690739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of lymphocyte to C-reactive protein ratio in predicting survival and postoperative complication for esophago-gastric junction cancer.
    Tsujiura M; Yamamoto A; Imaoka H; Shimura T; Kitajima T; Morimoto Y; Kawamura M; Yasuda H; Okita Y; Yokoe T; Okugawa Y; Ohi M; Toiyama Y
    Surg Oncol; 2022 Sep; 44():101842. PubMed ID: 36081281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Influence of the CONUT Score on Survival of Patients With Gastric Cancer Receiving Curative Treatment.
    Aoyama T; Komori K; Nakazano M; Hara K; Tamagawa H; Kazama K; Hashimoto I; Yamada T; Maezawa Y; Segami K; Kano K; Nagasawa S; Yukawa N; Rino Y; Ogata T; Oshima T
    In Vivo; 2022; 36(2):942-948. PubMed ID: 35241553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.
    Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oda Y; Mori M
    Int J Clin Oncol; 2021 Oct; 26(10):1890-1900. PubMed ID: 34251555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study.
    Cheng CB; Zhang QX; Zhuang LP; Sun JW
    Jpn J Clin Oncol; 2020 Sep; 50(10):1141-1149. PubMed ID: 32564084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer.
    Okugawa Y; Toiyama Y; Yamamoto A; Shigemori T; Ichikawa T; Yin C; Suzuki A; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; McMillan DC; Kusunoki M
    Clin Nutr; 2020 Apr; 39(4):1209-1217. PubMed ID: 31155370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer.
    Iseda N; Iguchi T; Hirose K; Itoh S; Honboh T; Sadanaga N; Matsuura H
    Am Surg; 2023 Nov; 89(11):4452-4458. PubMed ID: 35920820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.
    Matsunaga T; Saito H; Fukumoto Y; Kuroda H; Taniguchi K; Takahashi S; Osaki T; Iwamoto A; Fukuda K; Shimizu S; Shishido Y; Miyatani K; Fujiwara Y
    Surg Today; 2023 Aug; 53(8):940-948. PubMed ID: 36595075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer.
    Nishi M; Shimada M; Tokunaga T; Higashijima J; Yoshikawa K; Kashihara H; Takasu C; Ishikawa D; Wada Y; Eto S; Yoshimoto T
    World J Surg Oncol; 2021 Jul; 19(1):201. PubMed ID: 34229704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Naples Prognostic Score Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.
    Aoyama T; Kato A; Hashimoto I; Maezawa Y; Hara K; Kazama K; Komori K; Tamagawa H; Tamagawa A; Nagasawa S; Cho H; Segami K; Nakazono M; Otani K; Sawazaki S; Numata M; Kamiya N; Yoshizawa S; Kawahara S; Oshima T; Saito A; Yukawa N; Rino Y
    In Vivo; 2024; 38(2):890-896. PubMed ID: 38418121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8
    Miyazaki K; Morine Y; Imura S; Ikemoto T; Saito Y; Yamada S; Tokuda K; Okikawa S; Yamashita S; Oya T; Tsuneyama K; Shimada M
    Surg Today; 2021 Dec; 51(12):1985-1995. PubMed ID: 34009433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Benefit of the Modified Neutrophil-Platelet Score as a Surrogate Prognostic Marker in Patients With Resectable Gastric Cancer.
    Otani K; Aoyama T; Maezawa Y; Hashimoto I; Kamiya N; Kato A; Numata M; Kawahara S; Tamagawa A; Nakazono M; Tamagawa H; Segami K; Kazama K; Sawazaki S; Yukawa N; Saito A; Rino Y
    In Vivo; 2024; 38(2):897-903. PubMed ID: 38418135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy.
    Aoyama T; Yamamoto N; Kamiya M; Murakawa M; Tamagawa H; Sawazaki S; Numata M; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Anticancer Res; 2018 Aug; 38(8):4877-4882. PubMed ID: 30061263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C-reactive Protein to Prealbumin Ratio Is an Independent Prognostic Factor for Patients With Gastric Cancer Who Receive Curative Surgery.
    Aoyama T; Hashimoto I; Maezawa Y; Hara K; Komori K; Otani K; Kazama K; Sawazaki S; Numata M; Kamiya N; Kato A; Yamada T; Nagasawa S; Kawahara S; Cho H; Morita J; Tanabe M; Yukawa N; Saito A; Rino Y; Ogata T; Oshima T
    Anticancer Res; 2023 Nov; 43(11):5181-5187. PubMed ID: 37909998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Preoperative Plasma Fibrinogen Versus Other Prognostic Markers for Predicting Gastric Cancer Recurrence.
    Yamamoto M; Kurokawa Y; Miyazaki Y; Makino T; Takahashi T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    World J Surg; 2016 Aug; 40(8):1904-9. PubMed ID: 26969673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.